Source: Canadian Journal of Cardiology. Conference titles: Canadian Cardiovascular Congress (CCC). Unidade: EERP
Subjects: FARMACOVIGILÂNCIA, MEDICAMENTO, FÁRMACOS (SISTEMA CARDIOVASCULAR)
ABNT
AKINOLA, Pelumi Samuel et al. Can we use the canadian postmarketing spontaneous pharmacovigilance system for cardiovascular drug safety research?. Canadian Journal of Cardiology. New York: Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.cjca.2020.07.166. Acesso em: 04 fev. 2025. , 2020APA
Akinola, P. S., Silveira, C. G. da, Corbin, S., Lavallée, M., Thibault, M., Gonella, J. M., et al. (2020). Can we use the canadian postmarketing spontaneous pharmacovigilance system for cardiovascular drug safety research? Canadian Journal of Cardiology. New York: Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.cjca.2020.07.166NLM
Akinola PS, Silveira CG da, Corbin S, Lavallée M, Thibault M, Gonella JM, Sousa FREG de, Leclerc J. Can we use the canadian postmarketing spontaneous pharmacovigilance system for cardiovascular drug safety research? [Internet]. Canadian Journal of Cardiology. 2020 ; 36( 10): S83-S84.[citado 2025 fev. 04 ] Available from: https://doi.org/10.1016/j.cjca.2020.07.166Vancouver
Akinola PS, Silveira CG da, Corbin S, Lavallée M, Thibault M, Gonella JM, Sousa FREG de, Leclerc J. Can we use the canadian postmarketing spontaneous pharmacovigilance system for cardiovascular drug safety research? [Internet]. Canadian Journal of Cardiology. 2020 ; 36( 10): S83-S84.[citado 2025 fev. 04 ] Available from: https://doi.org/10.1016/j.cjca.2020.07.166